详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Sodium tanshinone IIA sulfonate for reduction of periprocedural myocardial injury during percutaneous coronary intervention (STAMP trial): Rationale and design

14| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China [2]Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China [3]Chinese Medicine Research Institute, Tianjin University of Chinese Medicine, Tianjin 300193, China [4]Physiology & Experimental Medicine, Hospital for Sick Children, Toronto M5G 0A4, Canada

出处：

DOI：

ISSN：

关键词： Sodium tanshinone IIA sulfonate Periprocedural myocardial infarction Non-ST-segment elevation acute coronary syndrome Percutaneous coronary intervention

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2014]版：

大类 | 2 区医学

小类 | 2 区心脏和心血管系统

最新[2025]版：

大类 | 2 区医学

小类 | 3 区心脏和心血管系统

JCR分区：

出版当年[2013]版：

Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

最新[2023]版：

Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子： 3.2 最新[2023版] 3.2 最新五年平均 6.175 出版当年[2013版] 5.101 出版当年五年平均 5.509 出版前一年[2012版] 4.036 出版后一年[2014版]

第一作者：

第一作者机构： [1]Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China [2]Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China [4]Physiology & Experimental Medicine, Hospital for Sick Children, Toronto M5G 0A4, Canada

通讯作者：

通讯机构： [1]Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China [2]Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China [*1]Department of Critical CareMedicine,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510120, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Efficacy of Sodium Tanshinone IIA Sulfonate in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Controlled, Randomized Trial [2]The relationship between hypersensitivity troponin T with coronary flow after acute non - ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention [3]Effect of Danlou Tablet on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: A study protocol of a multicenter, randomized, controlled trial [4]GW29-e0104 The relationship between hypersensitivity troponin T with coronary flow after acute non - ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention [5]Effect of COVID-19 Pandemic on Acute Coronary Syndrome Clinical Practice Patterns: Findings from a Multicenter Clinician Survey in China [6]Long-term prognostic value of RDW CV in patients with acute coronary syndrome undergoing percutaneous coronary intervention [7]GW29-e0105 Long-term prognostic value of RDW CV in patients with acute coronary syndrome undergoing percutaneous coronary intervention [8]Exploration of Multiple Signaling Pathways Through Which Sodium Tanshinone IIA Sulfonate Attenuates Pathologic Remodeling Experimenta Infarction [9]Long-term prognostic value of RDW CV in patients with acute coronary syndrome undergoing percutaneous coronary intervention [10]Sodium tanshinone IIA sulfonate protects against Aβ-induced cell toxicity through regulating Aβ process